Analysis to Next Generation Sequencing Technology

Recent years, with the invention and merchandising of second-generation sequencing generation, the gene sequencing velocity has extended substantially whilst reaching a vast decline in charges, making massive-scale application of genome sequencing feasible. Now, the cost of personal entire genome sequencing is set five,000$, and is expected to decreased to less than $ 1,000 in the following couple of years.

The rapid development of sequencing era will promote the big accumulation of DNA sequencing statistics, accompanied by using the accumulation of the corresponding character sicknesses, signs and other records on the identical time. When we accumulate sufficient data, a way to recognize those data may be crucial. On the micro stage, generations of molecular biologists’ reading the consequences of apparent organic tendencies genes exert on using technologies like gene knockout have made breakthroughs in many vital elements. On the macro degree, information and different statistics evaluation techniques are added to have a look at the connection between gene sequences and organic phenotype. The accumulation of primary clinical research step by step brings breakthroughs in scientific packages.

There are now two forms of clinical programs specially, one aims at ailment screening of everyday people. It infers human beings’s future risks of having most cancers by measuring the recognized genes associated with a ailment loci. The different pursuits on the prognosis cancer and different deadly sicknesses. It finds in a series of medicine or plans the simplest one for sure patients via testing the loci of positive genes.

Data from BBC studies indicates that overall international gene sequencing market expanded from $ 7.941million in 2007 to $ four.Five billion in 2013, and will attain $ 11.7 billion inside the year of 2018 with the CAGR as much as 21.2%.

Currently, the market of de novo sequence platform is especially taken by using several main producers, inclusive of the Illumina, Ion Torrent / Life Technologies (become the purchase of Thermo Fisher in 2014), 454 Life Sciences / Roche, and many others.

Under this kind of condition, the subsequent generation sequencing generation (second-technology sequencing) seems. As an emerging industry, the next-generation sequencing technology may be implemented in clinical checking out like antibody discovery, health industry, business and agricultural use of gene-oriented take a look at as well as clinical studies and development.